GLP-1 Telehealth Price Tracker: May–July 2026

GLP-1 telehealth prices moved in one direction this spring: down, and toward simpler structures. That is the short version of what RxPickr's pricing dataset shows between our May 2026 baseline and our July 2026 refresh. We track roughly 100 individual medication offerings across 18 providers (16 telehealth platforms plus the two manufacturer-direct programs, LillyDirect and NovoCare Pharmacy), and we verify every price against the provider's own public pricing pages or a completed intake quote. Snapshots are taken monthly. This article is the longitudinal view: what actually changed between May 4–8 and July 6, 2026, provider by provider.

The headline findings:

• The compounded semaglutide floor fell about 11%, from $149/month (Shed Microdose, all-inclusive) in May to $133/month (Oak Longevity, flat at every dose on a multi-month plan) in July. The full category band shifted from $149–$297/month to $133–$299/month.
• Six of the 18 providers made confirmed pricing or structure changes; nine were confirmed unchanged. Of the 11 providers currently selling compounded semaglutide, six changed something about how they price it.
• Every confirmed provider-side change to a recurring compounded rate moved down or went flat. The only cost increase we recorded was at the entry point: Enhance.MD retired its flat $49 and $99 first-month promos.
• Brand-name list prices did not move. Not one brand Wegovy, Zepbound, Ozempic, or Foundayo price changed at any provider whose brand catalog we track.
• The compounded tirzepatide premium collapsed at several providers. Found now charges the same $169/month for compounded tirzepatide as for semaglutide, down from a $348/month effective total in May.

GLP-1 medications require a prescription, so every price here assumes a licensed provider approves treatment for you. For the current cheapest options, see Cheapest GLP-1 Online in July 2026; for live rates, the pricing tool updates as providers change.

What changed, provider by provider

The table below covers every material movement between the two snapshots. We separate genuine provider-side changes from corrections to our own records, because a stale figure we fixed is not the same thing as a provider raising a price. All figures are self-pay monthly rates; "total" means medication plus any required membership.

Provider	May 2026 (our records)	July 2026 (verified)	What happened
Found	Compounded sema $149 + $99 membership ($248 total); compounded tirzepatide $249 + $99 ($348 total)	$169/mo all-in, medication included, same price for sema, tirzepatide, and liraglutide (12-month plan; ~$199 on 6-month, $289 month to month)	Provider change: membership dropped, split billing replaced by one all-in plan. Down $79–$179/mo.
Eden	Sema $209/mo all-in ongoing ($129 intro); tirzepatide $329/mo	$99/mo sema, $199/mo tirzepatide medication, flat at every dose, plus a new $99/mo membership ($39 first month). Totals: $198 sema, $298 tirzepatide	Provider change: membership added, medication price flattened. Totals down slightly.
Oak Longevity	Sema $183/mo starter, tirzepatide $250/mo starter, each dose step adding roughly $50–$75	Sema from $133/mo, tirzepatide from $199/mo, one flat price at every dose (multi-month plan; sema runs about $167–$199 month to month)	Provider change: dose-escalation pricing replaced with flat all-dose rates. Down, especially at maintenance doses.
Shed	Sema lozenges $299/mo; sema drops $329/mo and tirzepatide drops $419/mo	Lozenges $199/mo; drops consolidated into a single $229/mo GLP-1 Liquid Drops product	Provider change: non-injection formats cut $100–$190/mo. Injectables confirmed unchanged.
Noom Med	Microdose first month $99, then $199/mo	Microdose first month $79, then $199/mo	Provider change: intro price cut $20. Ongoing rate unchanged.
Enhance.MD	$49 first month (sema) and $99 first month (tirzepatide) on 12-month plans	Flat first-month promos retired, replaced by seasonal discount codes. Ongoing rates unchanged: $212 sema, $280 tirzepatide, $169 Microdose Tirzepatide	Provider change: entry cost up. The only increase in this cycle.
Ro	Compounded semaglutide listed (price gated behind account)	Compounded semaglutide discontinued; brand-name only	Provider change: catalog exit, following Hims' earlier move to brand-only.
TrimRx	Sema $179/mo, tirzepatide $259/mo	Sema $199/mo flat all-inclusive, tirzepatide $349/mo flat all-inclusive, $0 membership	Data correction: the $179 was a first-month rate and the $259 matched no current tier. Not a confirmed provider increase.
NovoCare Pharmacy	Ozempic $349/mo labeled as a starter price	$199/mo for the first two months, then $349/mo ongoing ($499 for the 2mg dose)	Data correction: our record mislabeled the ongoing price and missed the intro tier (per Ozempic savings page, July 2026).
Shed (brand)	Wegovy pen $149 + $125 membership; Zepbound $299 + $125	Wegovy pen $199 + $125; Zepbound from $349 + $125 (by dose)	Data correction: the pen had been recorded at the pill's price. Wegovy pill $149 and $125 membership confirmed correct.
Eden (brand)	Wegovy $199, Zepbound $299 (estimates)	Wegovy $1,695/mo, Zepbound $1,399/mo cash retail, plus membership	Data correction: prior figures were manufacturer-program estimates, not Eden's own cash prices.

Nine providers were confirmed unchanged in the July refresh: LillyDirect (Zepbound vials $299/$449 by dose, Foundayo $149–$349 ladder), NovoCare (Wegovy pill $149/mo; the Ozempic row in the table above corrected our record, not a Novo price change), PlushCare ($19.99/mo membership, brand-only), Mochi Health ($79 membership + $99 sema / $199 tirzepatide), Henry Meds (all five offerings, including the $179/mo sublingual sema), Hims ($149–$299 brand catalog + $149 membership), Hers (Zepbound vial $299 confirmed), bmiMD ($289 sema / $399 tirzepatide), and WeightWatchers Clinic ($74 membership, Wegovy $349 self-pay). MEDVi's public prices ($179 first month, $299 refill) were also re-confirmed, though its tirzepatide figure remains an estimate.

Trend 1: flat all-dose pricing is replacing dose escalation

The most visible structural shift this cycle is the death of the dose ladder among compounded providers. In May, Oak Longevity priced compounded semaglutide at $183/month for the starter dose with each titration step adding roughly $50–$75, so a patient reaching a maintenance dose paid meaningfully more than the headline. By July, Oak had moved to one flat price at every dose: semaglutide from $133/month, tirzepatide from $199/month.

Oak now joins TrimRx ($199 sema, $349 tirzepatide, flat across doses, no membership), Enhance.MD (same price at every dose), Eden (flat medication price at every dose), and Found (one plan price across compounded drugs and doses) in advertising dose-independent pricing. That is five of the 11 compounded semaglutide sellers we track.

This matters for buyers because dose-escalation pricing quietly raised real-world costs 3 to 6 months in, exactly when most patients titrate up. Flat pricing appears to be a competitive response to that pain point, though we can only observe the pricing pages, not the strategy behind them. If you compared providers in the spring using starter-dose prices, the ranking at maintenance doses looks different now.

Trend 2: membership fees are being restructured, in both directions

Two providers rebuilt their billing structure between snapshots, and they moved in opposite directions.

Found retired its split model, where a $149/month compounded medication charge stacked on a $99/month membership for a $248/month real total. Its GLP-1 Program now bundles the medication into one plan price: $169/month on the 12-month plan, about $199/month on the 6-month plan, and $289/month month to month, verified on Found's plans-and-pricing page in July 2026. At the low end that is $79/month cheaper than the May structure, and the quoted number is finally the number you pay.

Eden went the other way. It introduced a $99/month membership ($39 the first month) on top of medication prices that it simultaneously flattened to $99/month for semaglutide and $199/month for tirzepatide at every dose. The effective totals ($198 and $298) actually came down slightly from May's $209 and $329 all-in rates, but the advertised medication price no longer equals the real total.

The lesson from watching both moves side by side: a "medication price" and a "monthly total" are different numbers, and providers shift costs between the two lines. Our dataset and pricing tool always record both.

Trend 3: compounded prices are competing while brand prices hold still

Split the dataset into compounded and brand-name offerings and the contrast is stark. On the compounded side, every confirmed provider-side change to a recurring rate between May and July moved down or restructured flat: Found (down $79–$179/month in total), Eden (totals down $11–$31/month), Oak (headline down $50/month with the escalation ladder removed), and Shed (non-injection formats down $100–$190/month). The only upward movement was Enhance.MD retiring its first-month promos, an entry-cost change that left ongoing rates untouched.

On the brand side, nothing moved. LillyDirect, NovoCare, Hims, Hers, PlushCare, and WeightWatchers Clinic all reconfirmed their May brand pricing in July. Manufacturer self-pay programs appear to reprice on their own calendar (Lilly's current Zepbound vial tiers date to December 2025, per LillyDirect), not in response to month-to-month telehealth competition.

The compression is sharpest in compounded tirzepatide. In May, the category ran $169–$449/month and every provider priced tirzepatide well above semaglutide. By July the band was $169–$399, and at Found the premium disappeared entirely: compounded tirzepatide costs the same $169/month as semaglutide. Eden's gap narrowed from $120 to $100/month, and Oak's flat rates hold the gap to $66/month at every dose, where its old escalation model let both drugs climb. This is consistent with easier active-ingredient sourcing or simple price competition, but that is our reading of the numbers, not something any provider has stated.

One structural caveat belongs in any analysis of compounded pricing: compounded GLP-1 medications are made by licensed compounding pharmacies and are not FDA-approved as finished products. They contain the same active ingredient as the brand drug, but the finished formulation has not been reviewed by the FDA for safety, efficacy, or quality (FDA, 2025). Regulatory change here could reshape the price picture faster than any competitive dynamic. Ro's exit from compounded semaglutide this cycle, following Hims' move to brand-only after its agreement with Novo Nordisk, shows the large platforms already consolidating around FDA-approved products.

Trend 4: the $149 manufacturer-direct pill is becoming the price anchor

Two FDA-approved oral products now sit at $149/month direct from their manufacturers: Foundayo (orforglipron), which the FDA approved on April 1, 2026 as the first oral GLP-1 receptor agonist without food and water restrictions (FDA, April 2026), at $149/month for the 0.8mg starter dose via LillyDirect, and the Wegovy pill at $149/month (1.5mg and 4mg doses) via NovoCare Pharmacy.

Both are fulfillment-only programs: you bring your own prescription, and there is no telehealth visit or care team included. But their existence appears to function as a ceiling on what compounded providers can charge at entry. It is probably not a coincidence that the compounded semaglutide floor moved from $149 to $133 in the same window, and that Eden now advertises a $99/month medication price. When an FDA-approved pill costs $149 direct, a compounded product, which is not FDA-approved as a finished product, has to be visibly cheaper to make its case. Note that Foundayo's own ladder still escalates by dose, reaching $349/month at the top, so the anchor holds at entry doses more than at maintenance.

The current state: live July 2026 prices

The table below pulls from our live dataset, the same data behind the pricing tool, so it reflects the current verified state rather than the snapshot this article froze in time.

What this means if you're buying

Three practical rules fall straight out of the May-to-July data.

Verify the ongoing price at checkout, not the headline. The two biggest gaps in our dataset between advertised and real prices are first-month teasers and separate memberships. MEDVi's $179 first month becomes $299 on refill. Noom Med's $79 intro becomes $199. Mochi's $99 semaglutide carries a $79 membership; Eden's $99 now carries a $99 membership. Before enrolling anywhere, confirm the month-two price, whether a membership bills separately, and what dose the quote covers.

Price the commitment honestly. The lowest numbers in this article, Oak's $133 and Found's $169, assume multi-month or 12-month prepaid plans. Month to month, Oak's semaglutide runs about $167–$199 and Found's plan is $289. If you are not confident you will stay on treatment past a few months, the month-to-month rate is your real price, and the ranking changes.

Recheck the market if you priced it in spring. Anyone who compared providers in May using dose-escalation starter prices, Found's split billing, or Shed's old lozenge price is working from a stale map. The July cheapest-GLP-1 breakdown has the current category-by-category winners, the pricing tool has live filterable rates, and the quiz matches you to a provider based on your budget, insurance, and medication preference.

Citing this data

This price history is RxPickr's own original dataset. To our knowledge no other public source tracks verified GLP-1 telehealth prices longitudinally at the offering level. Journalists, researchers, and other publishers are welcome to cite or reproduce the figures with attribution to "RxPickr GLP-1 Price Tracker" and a link to this page or the pricing tool. If you need the underlying snapshot data or have a correction, contact us; we would rather fix a number than defend it.

Methodology and limitations

Snapshots. The May baseline was verified May 4–8, 2026, primarily by direct provider sign-up and pricing-page audits (documented in our May price report). The July refresh was completed July 6, 2026, with one researcher per provider re-verifying every offering against live provider pages.

Verification tiers. Most July prices were read directly from provider pricing pages loaded in a live browser session (Found, Oak, Shed, Eden, MEDVi, Noom Med, Mochi, Henry Meds, PlushCare, WeightWatchers Clinic, LillyDirect, NovoCare). A few providers block automated access to their sites, so their prices were corroborated through multiple independent 2026 third-party reviews instead (Hims, Hers, bmiMD). TrimRx's figures are third-party corroborated but not checkout-confirmed, and we label them accordingly in the dataset.

Known gaps still awaiting checkout verification. Found's brand-name medication prices are gated behind its intake survey and its membership structure for brand products changed this cycle, so those figures are provisional. The Hers Zepbound KwikPen price is unconfirmed (the pen is not part of Lilly's self-pay vial program). Enhance.MD's current promo-code first-month net prices and its combined sema-plus-tirzepatide tier are not yet priced. MEDVi publishes no tirzepatide-specific pricing, so its tirzepatide figure remains an estimate. Oak's oral semaglutide ($245) was not re-checked in July.

Scope. All prices are self-pay unless noted, exclude insurance coverage and manufacturer savings-card scenarios, can vary by dose and state, and change without notice. The snapshot comparison covers roughly 100 current offerings across 18 providers; offerings we removed as data errors (rather than provider changes) are excluded from the trend counts above.